Top Abstract Purchase Related
Home
>
Node
>
Subnode

Clinical Inquiries: What are the benefits and risks of daily low-dose aspirin for primary prevention of CV events?

Mutter, J.; Grandy, R.; Hulkower, S.; Stigleman, S.

Journal of Family Practice 67(4): 247-248

2018

ISSN/ISBN: 0094-3509
PMID: 29614147
Document Number: 697711
One nonfatal myocardial infarction (MI) will be avoided for every 126 to 138 adults who take daily aspirin for 10 years (strength of recommendation [SOR]: A, systematic reviews and meta-analyses of multiple randomized controlled trials [RCTs]). Taking low-dose aspirin for primary prevention shows no clear mortality benefit. A benefit for primary prevention of stroke is less certain. Although no evidence establishes increased risk of hemorrhagic stroke from daily low-dose aspirin, one gastrointestinal hemorrhage will occur for every 72 to 357 adults who take aspirin for longer than 10 years (SOR: A, systematic reviews and meta-analyses of multiple RCTs and cohort studies).

Document emailed within 1 workday
Secure & encrypted payments

De Caterina, R. 2003: Low-dose aspirin in the primary prevention of cardiovascular disease: how to balance the benefits and the risks Italian Heart Journal: Official Journal of the Italian Federation of Cardiology 4(4): 228-231
Selak, V.; Jackson, R.; Poppe, K.; Kerr, A.; Wells, S. 2018: Are the benefits of aspirin likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of cardiovascular disease? New Zealand Medical Journal 131(1484): 19-25
Pignone, M.; Mulrow, C. 2002: Antiplatelet therapy and atherosclerotic events. Risks and patients' values need to be included in decision about aspirin for prevention of coronary heart disease Bmj 324(7342): 917
Stalnikowicz-Darvasi, R. 1995: Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events. A critical analysis Journal of Clinical Gastroenterology 21(1): 13-16
Guo, Y.F. 2019: Effects of aspirin on primary prevention of cardiovascular events in patients with hypertension Zhonghua Nei Ke Za Zhi 58(4): 249-251
Iavelov, I.S. 2006: Aspirin in primary prevention of cardiovascular events in women and men (a meta-analysis of randomized controlled trials) Kardiologiia 46(3): 75-76
Gaciong, Z. 2006: Clopidogrel and aspirin versus aspirin alone in prevention of atherothrombotic events. The results of CHARISMA study Kardiologia Polska 64(5): 548
Kalantzi, K.I.; Ntalas, I.V.; Chantzichristos, V.G.; Tsoumani, M.E.; Adamopoulos, D.; Asimakopoulos, C.; Bourdakis, A.; Darmanis, P.; Dimitriadou, A.; Gkiokas, S.; Ipeirotis, K.; Kitikidou, K.; Klonaris, I.; Kostaki, A.; Logothetis, D.; Mainas, K.; Mais, T.; Maragiannis, A.; Martiadou, K.; Mavronasos, K.; Michelongonas, I.; Mitropoulos, D.; Papadimitriou, G.; Papadopoulos, A.; Papaioakeim, M.; Sofillas, K.; Stabola, S.; Stefanakis, E.; Stergiou, D.; Thoma, M.; Zenetos, A.; Zisekas, S.; Goudevenos, J.A.; 2019: Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial Current Vascular Pharmacology 17(6): 635-643
De Caterina, R. 2001: The Primary Prevention Project Study Group. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice Italian Heart Journal. Supplement: Official Journal of the Italian Federation of Cardiology 2(6): 681-684
Upton, A.C. 1981: Low-dose radiation: risks vs benefits Postgraduate Medicine 70(6): 34-7 40-1 45-7
Hiatt, W.R. 2008: Aspirin for prevention of cardiovascular events Bmj 337: A1806
Katz, L.B.; Shriver, D.A. 1989: Rioprostil heals pre-existing aspirin-induced gastric lesions in dogs during daily aspirin administration without altering the anti-inflammatory or analgesic efficacy of aspirin Journal of Pharmacology and Experimental Therapeutics 251(2): 774-781
Young, F.E.; Nightingale, S.L.; Temple, R.A. 1988: The preliminary report of the findings of the aspirin component of the ongoing Physicians' Health Study. The FDA perspective on aspirin for the primary prevention of myocardial infarction JAMA 259(21): 3158-3160
Silverberg, D.S.; Rotmensch, H.H.; Iaina, A. 1995: Low-dose thiazides in the treatment of hypertension: benefits and risks in perspective Journal of Human Hypertension 9(11): 869-873
Junker, J.A.; Aitken, P.V.; Flake, D.; Yousefi, P. 2004: Clinical inquiries. how should we treat chronic daily headache when conservative measures fail? Journal of Family Practice 53(10): 825-827
Yokoyama, T.; Yamashita, K.; Yamasaki, F.; Ueta, T.; Manabe, M.; Nishiyama, T. 2003: Aspirin reversal--an incremental administration of aspirin shortens the bleeding time prolonged by low-dose aspirin Masui. Japanese Journal of Anesthesiology 52(4): 399-401
Nordt, T. 2001: Primary prevention of cardiovascular events by ASS and vitamin E. PPP--Primary Prevention Project Der Internist 42(12): 1705-1707
De Gaudemaris, R.; Battistella, P.; Siche, J.P.; Debru, J.L.; Blatier, J.F.; Mallion, J.M. 1986: Comparative study of the efficacy of captopril at a single daily dose of 100 mg and at a twice daily dose of 50 mg by measuring ambulatory pressure over 24 hours Postgraduate Medical Journal 62 Suppl. 1: 97-100
Tollemar, J.; Tydén, G.; Brattström, C.; Groth, C.G. 1988: Anticoagulation therapy for prevention of pancreatic graft thrombosis: benefits and risks Transplantation Proceedings 20(3): 479-480
Olsson, J.E. 1979: Aspirin dose in prevention of transient ischaemic attacks Lancet 1(8120): 830